15 completed, 3 terminated, 1 recruiting, 1 unknown. 5 Phase 1, 5 Phase 2, 3 Phase 3, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Terminated 2, Recruiting 1 |
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Phase 3 | 3 | Completed 3 |
| Phase 4 | 3 | Completed 3 |
Follow Tumor Lysis Syndrome: new trials by email Literature Review of Tumor Lysis Syndrome trials Research Report on Tumor Lysis Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies Lonitoclax (ZE50-0134) - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) | Phase 1 | Recruiting | Lomond Therapeutics Holdings, Inc. | 84 | 2025-04-08 | 2026-07-31 |
| Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome Pegloticase, Rasburicase - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 4 | Completed | M.D. Anderson Cancer Center | 10 | 2022-04-05 | 2026-05-06 |
| A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma fractionated first dose rituximab - Aggressive B-Cell Non-Hodgkin Lymphoma | Unknown | University Hospital, Geneva | 94 | 2020-08-24 | 2023-05-06 | |
| A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors AZD0466 - Advanced Solid Tumors, Lymphoma | Phase 1 | Terminated | AstraZeneca | 9 | 2019-12-16 | 2023-08-02 |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Obinutuzumab, Bendamustine, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 3 | Completed | AbbVie | 120 | 2018-08-10 | 2024-08-06 |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) Revlimid - Lymphoma | Completed | Celgene | 1149 | 2017-05-30 | 2025-03-30 | |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat - Tumor Lysis Syndrome | Phase 1 / Phase 2 | Terminated | Menarini Group | 30 | 2017-02-27 | 2021-06-03 |
| A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg Multiple Myeloma | Completed | Celgene | 1149 | 2015-04-30 | 2022-07-05 | |
| Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies Febuxostat, Allopurinol - Tumor Lysis Syndrome | Phase 3 | Completed | Menarini Group | 346 | 2012-10-01 | 2014-11-03 |
| Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Rasburicase, Allopurinol - Leukemia, Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 55 | 2011-04-01 | 2020-01-31 |
| A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use Multiple Myeloma | Completed | Celgene | 361 | 2011-02-18 | 2022-06-14 | |
| A Study of Special Use Results Surveillance of Revlimid 5mg Capsules Multiple Myeloma, Myelodysplastic Syndromes | Completed | Celgene | 4626 | 2010-07-20 | 2022-06-14 | |
| Elitek (Rasburicase) Immuno-Monitoring Study Tumor Lysis Syndrome | Terminated | Sanofi | 1 | 2010-02-01 | 2013-01-31 | |
| Rasburicase in Patients at Risk for Tumor Lysis Syndrome As Needed Rasburicase, Fixed Dose Rasburicase - Tumor Lysis Syndrome | Phase 2 | Completed | M.D. Anderson Cancer Center | 82 | 2008-01-01 | 2013-08-01 |
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma Flavopiridol - Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2006-11-27 | 2018-01-30 |
| Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS Rasburicase - Leukemia, Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 18 | 2006-07-01 | 2012-08-01 |
| Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients Rasburicase - Leukemia, Lymphoma | Completed | St. Jude Children's Research Hospital | 16 | 2005-03-01 | 2017-04-25 | |
| Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome Rasburicase (SR29142), Allopurinol - Tumor Lysis Syndrome, Cancer | Phase 3 | Completed | Sanofi | 280 | 2004-04-01 | 2010-01-12 |
| Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Rasburicase (SR29142) - Tumors, Hyperuricemia | Phase 4 | Completed | Sanofi | 94 | 2004-03-01 | 2009-03-30 |
| Fasturtec TLS Treatment / Prophylysis urate oxidase - Tumor Lysis Syndrome | Phase 4 | Completed | Sanofi | 45 | 2003-07-01 | 2008-04-03 |
Lymphoma (10) · Leukemia (7) · Arrhythmias, Cardiac (4) · Heart Failure (4) · Hematologic Neoplasms (4) · Hypersensitivity (4) · Hyperuricemia (4) · Infections (4) · Lung Diseases, Interstitial (4) · Multiple Myeloma (4) · Peripheral Nervous System Diseases (4) · Teratogenesis (4) · Hemorrhage (3) · Myelodysplastic Syndromes (3)
Hemic and Lymphatic Diseases (20) · Immune System Diseases (20) · Immunoproliferative Disorders (20) · Lymphatic Diseases (20) · Lymphoproliferative Disorders (20) · Hematologic Diseases (16) · Neoplasms by Histologic Type (15) · Neoplasms (14) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Cardiovascular Diseases (6) · Vascular Diseases (6) · Blood Protein Disorders (5) · Disease Attributes (5) · Hemorrhagic Disorders (5)
rasburicase (8) · Urate Oxidase (4) · Allopurinol (3) · Febuxostat (2) · AZD0466 (1) · Amides (1) · Bendamustine Hydrochloride (1) · Carbamates (1) · Lenalidomide (1) · Oxidoreductases (1) · Pegloticase (1) · Uric Acid (1) · alvocidib (1) · obinutuzumab (1) · venetoclax (1)
Celgene (4) · M.D. Anderson Cancer Center (4) · Sanofi (4) · Menarini Group (2) · AbbVie (1) · AstraZeneca (1) · Lomond Therapeutics Holdings, Inc. (1) · National Cancer Institute (NCI) (1) · St. Jude Children's Research Hospital (1) · University Hospital, Geneva (1)
United States (14) · Japan (4) · Bulgaria (1) · Hungary (1) · Italy (1) · Spain (1) · Switzerland (1)
Saroj Vadhan-Raj, MD (2) · Angela Capriati, MD, PhD (1) · Franco Locatelli, Prof, MD (1) · Jinshu Cho (1) · Mark Roschewski, M.D. (1) · Michele Spina, MD (1) · Noemie Lang, MD (1) · Raul C. Ribeiro, MD (1) · Saroj Vadhan-Raj, M.D. (1) · Sharon Chang (1)
PMID 22015451, PMID 26216382, PMID 39410860
2016 (1)